Brief: Tenaya Therapeutics To Announce Initial Data From Mypeak-1 Phase 1B/2 Clinical Trial Of TN-201 Gene Therapy For Mybpc3-Associated Hypertrophic Cardiomyopathy On Tuesday, December 17, 2024
16/12/2024 21:31
Dec 16 (Reuters) - Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS TO ANNOUNCE INITIAL DATA FROM MYPEAK-1
PHASE
1B/2 CLINICAL TRIAL OF TN-201 GENE THERAPY FOR MYBPC3-ASSOCIATED
HYPERTROPHIC CARDIOMYOPATHY ON TUESDAY, DECEMBER 17, 2024
Source text: ID:nGNX9bXFcc
Further company coverage: TNYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027